Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabienne Thomas

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Pharmaceuticals (Basel, Switzerland)|March 6, 2021
Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite DataFélicien Le Louedec, Fanny Gallais, Fabienne Thomas, et al.
Clinical Pharmacology and Therapeutics|November 22, 2022
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!Fabienne Thomas, Manon Launay, Jérôme Guitton, et al.
Cancer Chemotherapy and Pharmacology|December 2, 2005
In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFRDiane Balin-Gauthier, Jean-Pierre Delord, Philippe Rochaix, et al.
Clinical Pharmacokinetics|December 24, 2005
Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatinFabienne Thomas, Sophie Séronie-Vivien, Laurence Gladieff, et al.
Journal of Medical Virology|November 30, 2006
Genetic diversity of HCV genotype 2 strains in south western FranceFabienne Thomas, Florence Nicot, Karine Sandres-Sauné, et al.
Clinical Pharmacokinetics|April 27, 2016
Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer PatientsLitaty Céphanoée Mbatchi, Jacques Robert, Marc Ychou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2011
Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in childrenMelanie White-Koning, Elodie Civade, Birgit Geoerger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2010
Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancerSébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, et al.
JCO Precision Oncology|March 17, 2023
Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case ReportFrançois Poumeaud, Florence Dalenc, Quentin Mathevet, et al.
Metabolites|September 23, 2022
Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver InjuryMaud Maillard, Cécile Arellano, Christelle Vachoux, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Pharmaceuticals (Basel, Switzerland)|March 6, 2021
Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite DataFélicien Le Louedec, Fanny Gallais, Fabienne Thomas, et al.
Clinical Pharmacology and Therapeutics|November 22, 2022
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!Fabienne Thomas, Manon Launay, Jérôme Guitton, et al.
Cancer Chemotherapy and Pharmacology|December 2, 2005
In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFRDiane Balin-Gauthier, Jean-Pierre Delord, Philippe Rochaix, et al.
Clinical Pharmacokinetics|December 24, 2005
Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatinFabienne Thomas, Sophie Séronie-Vivien, Laurence Gladieff, et al.
Journal of Medical Virology|November 30, 2006
Genetic diversity of HCV genotype 2 strains in south western FranceFabienne Thomas, Florence Nicot, Karine Sandres-Sauné, et al.
Clinical Pharmacokinetics|April 27, 2016
Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer PatientsLitaty Céphanoée Mbatchi, Jacques Robert, Marc Ychou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2011
Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in childrenMelanie White-Koning, Elodie Civade, Birgit Geoerger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2010
Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancerSébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, et al.
JCO Precision Oncology|March 17, 2023
Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case ReportFrançois Poumeaud, Florence Dalenc, Quentin Mathevet, et al.
Metabolites|September 23, 2022
Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver InjuryMaud Maillard, Cécile Arellano, Christelle Vachoux, et al.
Pageof 9